Tag
45 posts tagged “research”.
A measured, harm-reduction look at orforglipron, a non-peptide GLP-1 pill approved for obesity, and what actually matters to track.
A measured, harm-reduction look at MK-677, what it actually does to GH and IGF-1, and the daily signals and bloodwork worth watching.
A neutral, harm-reduction guide to the oral semaglutide weight-management pill, its strict dosing rules, and what to monitor.
A neutral, harm-reduction look at ostarine, why it is the mildest of the SARMs, and what to monitor given it still suppresses natural hormones.
A harm-reduction look at CagriSema, an investigational amylin-plus-GLP-1 combination not yet approved, and what would be worth tracking.
A harm-reduction look at ligandrol, why its strength comes with strong hormonal suppression, and the monitoring that actually matters.
A neutral, harm-reduction guide to mazdutide, a dual glucagon/GLP-1 agonist approved in China, and what to monitor.
A harm-reduction look at RAD-140, its strong anabolic effect, the reported liver-injury signals, and what to monitor closely.
A harm-reduction look at survodutide, an investigational GLP-1/glucagon agonist with obesity and MASH data, not yet approved.
A candid, harm-reduction look at cardarine, its endurance and fat-oxidation effects, and the rodent carcinogenicity signal that ended its development.
A neutral, harm-reduction guide to amycretin, an investigational GLP-1/amylin agonist in oral and injectable forms, entering Phase 3.
A harm-reduction look at andarine, its use in cutting phases, and the reversible vision side effect that sets it apart from other SARMs.
A harm-reduction look at VK2735, an investigational GIP/GLP-1 agonist in oral and injectable Phase 3 programs, not yet approved.
A harm-reduction look at YK-11, a steroidal compound sold as a SARM with myostatin-inhibition claims, and why the human evidence is essentially absent.
A neutral, harm-reduction guide to pemvidutide, an investigational GLP-1/glucagon agonist noted for lean-mass sparing and MASH data.
A harm-reduction look at SR9009, its exercise-mimetic claims, and the poor oral bioavailability that undercuts most real-world use.
A harm-reduction look at bimagrumab, an investigational antibody that lowers fat while preserving or adding muscle, studied with semaglutide.
A measured, harm-reduction look at enclomiphene, why it is used instead of exogenous testosterone, and the bloodwork that tells you whether it is working.
A harm-reduction look at methasterone, a potent and markedly hepatotoxic oral steroid, and the monitoring that matters most if someone has already decided to use it.
A cautious, harm-reduction look at cabergoline, why it is used to manage prolactin, and the cardiac risk that has to be taken seriously.
A harm-reduction look at fluoxymesterone, a strong oral steroid used pre-competition for strength and aggression, with honest framing of its liver and lipid risks.
A measured, harm-reduction look at raloxifene, why it is often preferred for treating gynecomastia, and the clotting risk to watch.
A measured look at mesterolone, a weakly anabolic oral DHT derivative used as an adjunct to lower SHBG and support libido, and what is worth tracking.
A measured, harm-reduction look at toremifene, how it compares to tamoxifen, and what to monitor when it is used for gyno control or PCT.
A harm-reduction look at trestolone, a very potent nandrolone-like injectable that is strongly suppressive and aromatizes to a potent estrogen, and what to monitor.
A balanced, harm-reduction look at finasteride and dutasteride, how they cut DHT for hair loss, and the honest tradeoffs including post-finasteride syndrome.
A harm-reduction look at dihydroboldenone, a non-aromatizing injectable anabolic notorious for post-injection pain, and the monitoring worth doing.
A measured, harm-reduction look at testosterone undecanoate in both its very long-ester injectable and oral forms, and the bloodwork that actually matters.
A cautious, harm-reduction look at clenbuterol, a stimulant thermogenic with real cardiac risk, and what to monitor if you have already decided to use it.
A measured look at liothyronine (T3), why it is used for fat loss, and the muscle and cardiac risks that come with suppressing your own thyroid.
An evidence-aware look at rapamycin, the headline off-label longevity drug, what the human data actually shows, and what to monitor on intermittent dosing.
An evidence-aware look at urolithin A, a gut-derived metabolite with human muscle and endurance data, sold as a well-tolerated supplement.
An evidence-aware look at spermidine, a dietary polyamine linked to autophagy and longevity signals, sold as a wheat-germ-derived supplement.
An evidence-aware look at fisetin, a plant flavonoid used in intermittent senolytic protocols, and why the human data is still mostly preliminary.
A blunt harm-reduction guide to DNP, a mitochondrial uncoupler with a narrow margin between fat loss and death, for people who have already obtained it.
A measured look at the classic racetam nootropics, how the common variants differ, and how to track whether they do anything for you.
Why SNAP-8 is a cosmetic ingredient rather than an injectable, and how to track whether it actually softens expression lines.
A measured look at Matrixyl, the topical collagen-stimulating peptide, and how to track whether it does anything for your skin.
A cautious, harm-reduction look at follistatin and ACE-031, why the human evidence is thin, and what to log if you use them anyway.
A measured look at Dihexa, why almost all of the evidence is in animals, and what a careful self-experimenter would actually log.
What Cerebrolysin is, why the stroke evidence is genuinely mixed, and the metrics worth logging if you use it.
A spadin analog that targets TREK-1. What the mechanism implies, why it is research-only, and what to log.
What P21 is, why the human evidence is essentially zero, and how to track it honestly if you choose to experiment at all.
A practical look at proprietary blends like KLOW, and why tracking them honestly means accepting you cannot isolate any one ingredient.
What B7-33 is, why it is studied in fibrosis and cardiac research, and why human tracking is currently very limited.